An Open-label, Randomized, Four-way Cross-over, Single Oral Dose Study Comparing the Pharmacokinetics of Four Different Formulations of AZD9977 (Part A) and Influence of Food (Part B) in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2018
At a glance
- Drugs AZD 9977 (Primary)
- Indications Diabetic nephropathies
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 14 Jun 2018 Status changed from active, no longer recruiting to completed.
- 04 May 2018 Status changed from recruiting to active, no longer recruiting.
- 04 May 2018 Planned End Date changed from 6 Jun 2018 to 31 May 2018.